GoodRx, Sanofi partner on $35 insulin
It’s unclear how much the partnership will move the needle on affordability given other recent actions from the French drugmaker and public insurance programs to lower insulin prices.
It’s unclear how much the partnership will move the needle on affordability given other recent actions from the French drugmaker and public insurance programs to lower insulin prices.